healthFriday, June 19, 2026

Alzheimer's eye test and NIH funding fight

Today's health news is split between early detection and political fights. A new retinal imaging technique could spot Alzheimer's years before symptoms, while a piece on lenacapavir makes the case for preserving NIH funding. Meanwhile, industry-backed bills aim to shield pesticide makers from lawsuits, and a heatwave in Europe is forcing event cancellations.

Sources

Early detection

Two pieces point to earlier intervention in neurodegenerative disease, from eye scans to AI-powered trials.

#01www.sciencealert.comJun 19

A Signal of Future Alzheimer's May Be Hidden in Your Eyes

Retinal imaging could predict Alzheimer's risk years before diagnosis. The retina is neural tissue, so changes there may signal brain disease early and non-invasively.

4 min readRead original

#02www.dementiaresearcher.nihr.ac.ukJun 19

AI Enabled Trials in Neurodegeneration - DEMENTIA RESEARCHER

The DEMON Network and LifeArc summit explored how AI can redesign clinical trials for neurodegeneration. The focus is on trial design, delivery, and evaluation, not just diagnosis.

22 min readRead original

Funding and policy

The fight over research funding and corporate liability shapes the landscape for new treatments.

#03www.thinkglobalhealth.orgJun 19

Lenacapavir: the HIV Breakthrough Proving Why NIH Funding Matters | Think Global Health

Lenacapavir, a breakthrough HIV drug, is used as a case study to argue against proposed 40% NIH funding cuts. The piece says publicly funded basic research was essential to the drug's development.

#04dlvr.itJun 19

The quiet push to shield pesticide makers from lawsuits

Industry-backed bills across U.S. states would give pesticide makers immunity from lawsuits, even when products allegedly cause cancer. The story highlights a California farmer whose husband died after using Roundup.